How Adaptive Design Accelerates Early‑Phase NSCLC Development

By Amy Pace, ScD, Vice President, Biostatistics, Pengfei Song, Ph.D., Vice President, Regulatory Strategy, and Charlotte Moser, M.D., Ph.D., M.B.A., Chief Medical Officer

Non‑small cell lung cancer (NSCLC) remains one of the most complex and competitive areas of oncology drug development, shaped by increasing molecular segmentation and evolving regulatory expectations. Advances in biomarker science, combined with the FDA’s Project Optimus, are shifting early‑phase development away from identifying a maximum tolerated dose toward selecting an optimized, effective dose range.

This article explores how adaptive trial designs—paired with an adaptive, cross-functional mindset—can accelerate early‑phase NSCLC development while reducing downstream risk. Seamless Phase I/II designs, model‑assisted dose escalation, planned backfilling, and randomized dose optimization allow sponsors to integrate proof of concept, dose finding, and expansion within a single program. Real‑time data analysis and pre‑planned adaptations enable rapid responses to emerging safety, PK/PD, and efficacy signals while maintaining regulatory alignment.

Success also requires organizational flexibility and strong cross‑functional decision‑making. Together, adaptive design and adaptive thinking provide a competitive advantage—helping sponsors accelerate development, strengthen investor confidence, and deliver effective therapies to patients sooner.